Glaukos Corporation is a healthcare company focused on developing innovative therapies for the treatment of glaucoma and other eye diseases. Its core products include micro-invasive surgical devices and pharmaceuticals aimed at lowering intraocular pressure. The company operates primarily in the ophthalmic surgical segment, with major revenue sources stemming from its proprietary devices and surgical procedures. Glaukos aims to enhance patient outcomes through advanced technology and minimally invasive solutions.
The investment profile of Glaukos suggests it may be more suitable for growth investors, given its focus on innovation and potential for revenue expansion. The company has demonstrated strong revenue growth quarter-over-quarter, indicating a positive trajectory. However, the absence of dividends and negative earnings per share suggests a focus on reinvestment rather than immediate returns. Investors should consider their risk tolerance and investment horizon when evaluating this stock.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-11-03 | — | Buy | Strong momentum and revenue growth support bullish outlook. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-10-29 | H.C. Wainwright | Target Raised | 195 → 248 | 237.73 |
| 2026-10-29 | Stifel Nicolaus | Target Raised | 190 → 225 | 181.43 |
| 2026-10-29 | Piper Sandler | Target Raised | 195 → 240 | 181.43 |
| 2026-10-29 | Needham | Target Raised | — → 251 | 181.43 |
| 2026-10-29 | Mizuho Securities | Target Raised | — → 225 | 181.43 |
| 2026-10-29 | Truist Financial | Target Raised | — → 255 | 181.43 |
| 2026-10-13 | Mizuho Securities | Target Raised | 185 → 190 | 168.02 |
| 2026-10-12 | BTIG | Target Raised | 202 → 205 | 166.055 |
| 2026-09-22 | Jefferies | Target Raised | 190 → 210 | 162.235 |
| 2026-08-20 | BTIG | Target Raised | 193 → 202 | 189.55 |
